Nakano City

This research aims to evaluate the antiviral effects of S-337395 compared with a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. Participants must start treatment within 72 hours of showing RSV symptoms. The study is a Phase 2b trial and involves adults with specific risk factors such as older age and chronic lung or cardiovascular disease. Participants will be randomly assigned to receive either a high dose or low dose of S-337395, or a matching placebo. The treatment is given orally twice daily for up to 5 days. The study is double-blind, meaning neither participants nor researchers know which treatment is being administered during the trial. Throughout the study, participants will be monitored closely with assessments including nasal swabs to measure RSV RNA levels at several time points up to day 6. Researchers will also track symptoms using questionnaires and record any side effects up to 28 days. Blood samples will be collected to measure drug levels, and safety will be monitored throughout the study, which runs until December 2026.

Researchers are evaluating the effectiveness and safety of a new investigational device compared to the standard autologous iliac bone graft ICBG for patients needing bone fusion through spinal fixation at two levels in the lower spine L2-S1. This study focuses on individuals with disc degeneration or spinal deformity requiring intervertebral support and spine stabilization. It is a prospective, multi-center, open-label, randomized clinical trial aiming to assess treatment outcomes in this patient group. Participants will be randomly assigned to receive either the investigational device MDT-0123, which includes a spine cage and a kit, or the standard treatment using the MDT-0123 spine cage combined with ICBG. The goal is to compare these two approaches for lumbar vertebral fusion over a treatment period. The study is conducted before the market release of the device and follows a parallel group design. During the trial, participants will undergo assessments over 12 months to measure success and safety, including changes in disc height, general health condition, disability index, and pain levels in the lower back and legs. Researchers will also track the time required for bone fusion. Participants will have regular follow-ups to monitor outcomes and safety. The total study period extends up to 12 months after the procedure, with detailed evaluations to understand the effectiveness of the treatments.